Pathways to ensure universal and affordable access to hepatitis C treatment

Direct-acting antivirals (DAAs) have dramatically changed the landscape of hepatitis C treatment and prevention. The World Health Organization has called for the elimination of hepatitis C as a public health threat by 2030. However, the discrepancy in DAA prices across low-, middle- and high-income...

Descripción completa

Detalles Bibliográficos
Autores principales: Douglass, Caitlin H., Pedrana, Alisa, Lazarus, Jeffrey V., ‘t Hoen, Ellen F. M., Hammad, Radi, Leite, Ricardo Baptista, Hill, Andrew, Hellard, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176525/
https://www.ncbi.nlm.nih.gov/pubmed/30296935
http://dx.doi.org/10.1186/s12916-018-1162-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176525/
https://www.ncbi.nlm.nih.gov/pubmed/30296935
http://dx.doi.org/10.1186/s12916-018-1162-z

Ejemplares similares